Ubs Oconnor LLC Phathom Pharmaceuticals, Inc. Transaction History

Ubs Oconnor LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$6.21 - $11.05 $90,827 - $161,617	-14,626 Reduced 33.85%	28,583 $303,000
Q4 2023 Feb 14, 2024	SELL	$6.99 - $10.71 $517,756 - $793,300	-74,071 Reduced 63.16%	43,209 $394,000
Q3 2023 Nov 14, 2023	SELL	$10.26 - $15.7 $235,980 - $361,100	-23,000 Reduced 16.4%	117,280 $1.22 Million
Q2 2023 Aug 14, 2023	BUY	$7.28 - $14.32 $1.02 Million - $2.01 Million	140,280 New	140,280 $2.01 Billion
Q1 2023 May 15, 2023	SELL	$6.19 - $12.36 $334,260 - $667,440	-54,000 Reduced 35.04%	100,093 $714,000
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $174,420 - $326,970	27,000 Added 21.24%	154,093 $1.71 Billion
Q2 2022 Aug 12, 2022	BUY	$6.2 - $15.5 $555,464 - $1.39 Million	89,591 Added 238.9%	127,093 $1.07 Million
Q1 2022 May 16, 2022	BUY	$11.55 - $20.06 $433,148 - $752,290	37,502 New	37,502 $510,000

144

73.6M

42.3K

45.7K

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $294M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.